Affiliation: Amylin Pharmaceuticals
- Treatment with exenatide once weekly or twice daily for 30 weeks is associated with changes in several cardiovascular risk markersElaine Chiquette
Amylin Pharmaceuticals, San Diego, CA, USA
Vasc Health Risk Manag 8:621-9. 2012..Exenatide, a glucagon-like peptide 1 receptor agonist, improved glycemic control, obesity, hypertension, and dyslipidemia in patients with type 2 diabetes in clinical trials...